Dr. Gabriel Kremmidiotis, Ph.D., serves as Vice President Research and Development of Bionomics Limited. He is a Molecular geneticist and immunologist Dr. Gabriel Kremmidiotis joined the Company as Head of Bioinformatics in January 2002 and his role has since expanded to Vice President Discovery Research. Formerly Senior Medical Scientist at the Department of Cytogenetics & Molecular Genetics at the Women & Children Hospital in Adelaide, Dr. Kremmidiotis has several patent inventions on breast cancer tumour suppressor genes, including Bionomics' BNO 64 and BNO 1 genes as well as other tumour suppressor genes
Vice President - Research and Development
|Kremmidiotis has a Ph.D and a BS from Flinders University of South Australia and a BS from The University of Melbourne. He has published research findings in 23 internationallyrecognised scientific publications including Cell, Human Molecular Genetics and American Journal of Human Genetics, and is a member of the Human Genetics Society of Australasia.|
The company has return on total asset (ROA) of (6.29) % which means that it has lost $6.29 on every $100 spent on asset. This is way below average. Similarly, it shows return on equity (ROE) of (13.47) % meaning that it generated substantial loss on money invested by shareholders.
The company has accumulated 1.09 M in total debt with debt to equity ratio (D/E) of 0.04 which may suggest the company is not taking enough advantage from borrowing. Bionomics Ltd has Current Ratio of 4.42 suggesting that it is liquid and has the ability to pay its financial obligations in time and when they become due.
Entity SummaryBionomics Limited, a biotechnology company, engages in the discovery and development of therapeutics for the treatment of cancer and disorders of the central nervous system in Australia and France. Bionomics Ltd [BNO] is traded on Australian Securities Exchange in Australia. It is located in Thebarton, SA and employs 11 people. Filter other
|Click to run this filter|| |
Filter Other Insiders
| BNO Australian #AU000000BNO5AU
Benchmark S&P 500
Currency: AUD - Australian Dollar
Traded on Australian Securities Exchange
Bionomics Ltd has less than 1.0 (%) percent chance of experiencing financial distress in the next 2 years of operations.
Bionomics price boundaries
Promote Bionomics and Gabriel Kremmidiotis